. Author manuscript; available in PMC: 2021 Nov 16.

Published in final edited form as: Int J Cell Biol Physiol. 2021 Oct 13;4(1-2):1–12.

Table 6.

Neutralizing antibodies for Covid-19.

Antibody Name	Source	Neutralizing activity	Neutralizing mechanism
S230.15 And m396	Human	Neutralize human and palm civet SARS-CoV	Recognize epitopes (residues408, 442, 443, 460, 475) on SARS-CoV S1 protein, interfering with RBD–ACE2 receptor interaction⁶⁶
S109.8S 277. 14S230.15	Human	Neutralize human (Urbani, GZ02, CUHK-W1), palm civet (HC/SZ/61/03), and raccoon dog(A031G) SARS-CoV infectious clones containing S variants	Inhibit the binding of SARS-CoV RBD–ACE2 receptor⁶⁷
80RscFv	Human	Neutralize live SARS-CoV (strain Urbani) infection	Epitopes on SARS-CoV S1 (residues 261–672), blocking RBD–ACE2 binding and inhibiting syncytium formation⁶⁸
CR3022 CR3014 scFv	Human	Neutralize live SARS-CoV (strainHKU-39849) infection; CR3022 could neutralize CR3014 escape variants	Recognize epitopes on SARS-CoV RBD (residues 318–510); CR3022 binds SARS-CoV-2 RBD with high affinity⁶⁹; ⁷⁰
Tocilizumab and Sarilumab	Recombinant humanized monoclonal antibody	IL-6 receptor antagonists	Targeting IL-6 and its receptor (IL6R) by tocilizumab and siltuximab monoclonal antibodies could mitigate cytokine storm⁷¹
Bevacizumab	Recombinant humanized monoclonal antibody	VEGF inhibitor	Target vascular endothelial growth factor (VEGF), inhibit it and prevents acute lung injury (ALI) and ARDS⁷²